AI assistant
CURIS INC — Director's Dealing 2007
Jun 8, 2007
34952_dirs_2007-06-08_605e066c-1ca3-4ce8-9c91-1bc20473c5c7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CURIS INC (CRIS)
CIK: 0001108205
Period of Report: 2007-06-06
Reporting Person: Qian Changgeng (VP, Research & Preclinical Dev)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2007-06-06 | Qualified stock option (right to buy) | $1.39 | A | 79767 | Acquired | 2017-06-06 | Common stock (79767) | Direct |
| 2007-06-06 | Non-qualified stock option (right to buy) | $1.39 | A | 70233 | Acquired | 2017-06-06 | Common stock (70233) | Direct |
| 2007-06-06 | Qualified stock option (right to buy) | $1.39 | A | 71942 | Acquired | 2017-06-06 | Common stock (71942) | Direct |
| 2007-06-06 | Non-qualified stock option (right to buy) | $1.39 | A | 78058 | Acquired | 2017-06-06 | Common stock (78058) | Direct |
Footnotes
F1: Options in the aggregate will vest 25% on the one-year anniversary grant date, or June 6, 2008. Remaining options will vest at 6.25% each successive three-month period, with non-qualified options vesting first. Options will be fully vested four years from the grant date.
F2: Common stock subject to stock option award shall become exercisable on December 6, 2012 or upon the consummation of a collaboration, licensing or other similar agreement regarding the Targeted Cancer Drug Development Platform that includes an up-front cash payment of at least $10 million. For clarity, the cash payment shall be attributable to a nonrefundable license fee or other similar payment and shall not include an equity investment in Curis and any vesting is subject to such Executive Officer's continued service with the Curis.